PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Personalis, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$15.88+0.23 (+1.47%)

Close on Oct 19, 2026

Market cap: $1.67B
P/E (TTM): –
Dividend yield: –

Dividends

Personalis has not reported a dividend

No dividend per share appears in Personalis's annual filings since fiscal 2016.

Where these numbers come from

Parsed from the XBRL in Personalis's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PSNL.

Revenue growth-13.3% · median 20.2%

Gross margin12.7% · median 53.6%

Operating margin-164.1% · median -28.9%

Net margin-153.8% · median -26.5%

Company	Revenue	Growth
VCYT	$561.90M	+17.3%
FLGT	$323.93M	+6.8%
GRAL	$165.26M	+23.1%
BDSX	$102.94M	+34.5%
PSNL	$69.67M	-13.3%
MDXH	–	–

Company

Next earnings (est.): Nov 3, 2026, after close
Exchange: Nasdaq
Industry: Services-Medical Laboratories
Fiscal year ends: December 31
Employees: 260
Held by institutions: 79.6%
Auditor: BDO USA, P.C.
SEC CIK: 1527753

Advertisement
300 × 250